Table 3.
Chemotherapy options and their effect for angiosarcoma.
| Agent | Patients | N | Response/median survival (months) |
|---|---|---|---|
| Anthracyclines | Pooled analysis of 11 clinical trials for angiosarcoma from all sites Young et al. (58) |
108 | Response ratio: 25% for all sites PFS: 4.9, OS: 9.9 |
| Paclitaxel | Retrospective review of angiosarcoma from all sites Italiano et al. (71) |
34 | Response ratio: 29.5% for all sites |
| 68 | Response ratio: 53% for all sites Response ratio: 78% for CAS | ||
| ANGIOTAX study: phase-2 study including angiosarcoma from all sites Penel et al. (70) |
30 | Response ratio: 18% for all sites Response ratio: 89% for CAS | |
| ANGIOTAX plus study: phase-2 study comparing paclitaxel with/without bevacizumab from all sites (showing paclitaxel arm only) Ray-Coquard et al. (74) |
24 | Response ratio: 45.8% for all sites PFS: 6.6, OS: 19.5 |
|
| Retrospective study for head/neck CAS Fata et al. (69) |
9 | Response ratio: 89% for CAS | |
| Docetaxel | Retrospective study for CAS Nagano et al. (101) |
9 | Response ratio: 67% for CAS |
| Gemcitabine | Retrospective study with angiosarcoma from all sites Stacchiotti et al. (76) |
25 | Response ratio: 64% for all sites PFS: 7, OS: 17 |
PFS, progression-free survival; OS, overall survival; CAS, cutaneous angiosarcoma.